1% capsaicin topical liquid (CGS-200-1)
/ Vizuri Health Sci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 07, 2019
A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
(ACR-ARHP 2019)
- "CGS-200-5 was well-tolerated and efficacious following application to both knees for 60 minutes on 4 consecutive days. Due to the significant efficacy and good safety and tolerability observed in this study, further clinical development of CGS-200-5 is warranted."
Clinical • P2 data
October 29, 2019
Vizuri Health Sciences LLC to present CGS-200-5 knee pain results at the American College of Rheumatology Annual Meeting
(Businesswire)
- "Vizuri Health Sciences LLC...today announced that it has been selected to make an oral presentation of findings from a randomized, double blind Phase 2 osteoarthritis (OA) knee pain study (VZU00025, NCT03528369) at the American College of Rheumatology and the Association of Rheumatology Health Professionals’ 2019 Annual Meeting, which will take place from November 8-13 in Atlanta, Georgia."
P2 data
1 to 2
Of
2
Go to page
1